Tabimorelin Research Profiles: Growth Hormone Secretagogue Receptor Studies

 

Abstract:

Tabimorelin (NN703) is an orally active growth hormone secretagogue that functions as a ghrelin receptor (GHS-R1a) agonist. Unlike its parent compound, ipamorelin, tabimorelin exhibits a broader pharmacological footprint, stimulating growth hormone release while also modulating appetite and adiposity and interacting significantly with the CYP3A4 enzyme system. Clinical development advanced to Phase 2 for growth hormone deficiency before discontinuation due to lack of efficacy and CYP3A4 inhibition concerns. This profile examines the receptor pharmacology, endocrine effects, metabolic actions, and pharmacokinetic properties of tabimorelin, drawing on two decades of research that illuminate both the therapeutic potential and limitations of small-molecule ghrelin receptor agonists.

Introduction

The growth hormone secretagogue receptor (GHS-R1a) has been a target of intense pharmaceutical interest since its identification as the receptor for synthetic growth hormone-releasing peptides and, subsequently, the endogenous hormone ghrelin. Activation of this G-protein coupled receptor stimulates growth hormone (GH) release from the pituitary and also modulates appetite, energy balance, and adiposity through central and peripheral mechanisms.

Tabimorelin (also known as NN703) emerged from Novo Nordisk's medicinal chemistry programme as a peptidomimetic designed for oral bioavailability—a significant advantage over injectable GH therapy. Its development trajectory, from preclinical characterisation through Phase 2 clinical trials, provides a valuable case study in the challenges of targeting the ghrelin system for therapeutic benefit.

Receptor Pharmacology and Potency

Tabimorelin binds to the human recombinant GHS-R1a with a Ki of 50 nM and stimulates GH release from rat pituitary cells with an EC50 of 2.7 nM. . In cellular assays, the compound demonstrates potent agonist activity, with an EC50 of 18 nM in classical rat pituitary cell GH-releasing assays. These potency values place tabimorelin among the more potent small-molecule ghrelin receptor agonists, though direct comparisons with native ghrelin are complicated by differences in assay conditions and receptor species.

The compound is characterised as an orally active growth hormone secretagogue, distinguishing it from peptide-based GH-releasing hormone (GHRH) and earlier ghrelin mimetics that required parenteral administration. This oral bioavailability was a central design objective, enabling potential use as an alternative to daily GH injections.

Growth Hormone Release and Endocrine Selectivity

Clinical studies in healthy male volunteers established tabimorelin's dose-dependent stimulation of GH release. Following single oral doses ranging from 0.05 to 12 mg/kg, significant increases in GH area under the curve (AUC) were observed at the three highest dose levels (3.0, 6.0, and 12 mg/kg), with maximal GH concentrations significantly elevated at 1.5 mg/kg and above. Insulin-like growth factor-I (IGF-I) levels also increased significantly at 6.0 and 12.0 mg/kg doses, confirming downstream activation of the GH/IGF-I axis.

However, the endocrine selectivity of tabimorelin proved less clean than its parent compound, ipamorelin. While ipamorelin was specifically engineered to avoid stimulating adrenocorticotrophic hormone (ACTH) and cortisol release, tabimorelin exhibited a broader hormonal footprint. In the 7-day multiple-dose study, statistically significant increases in prolactin, thyroid-stimulating hormone (TSH), and ACTH were observed on day 1 at various dose levels, though no dose-response relationship was evident for TSH or ACTH. More concerning for chronic use, subtle individual increases in ACTH, cortisol, and prolactin were noted at doses above 3.0 mg/kg.

Metabolic and Orexigenic Effects

Beyond GH release, tabimorelin exhibits ghrelin-like metabolic effects. In lean control rats, tabimorelin treatment (50 mg/kg orally for 18 days) induced hyperphagia and adiposity, increasing total fat mass and body weight gain. These effects were associated with increased hypothalamic mRNA expression of the anabolic neuropeptide Y (NPY) and decreased expression of the catabolic peptide pro-opiomelanocortin (POMC), indicating central mechanisms involving the arcuate nucleus.

Critically, these orexigenic and adipogenic effects were abolished in leptin-receptor-mutated Zucker diabetic fatty (ZDF) rats. While tabimorelin still increased NPY mRNA in the hypothalamic arcuate nucleus of ZDF rats, POMC mRNA expression was not suppressed, and hyperphagia and adiposity did not develop. This finding demonstrated that intact leptin-receptor signalling is required for tabimorelin's full metabolic effects, revealing a previously unrecognised dependency between ghrelin and leptin pathways in energy balance regulation.

Pharmacokinetics and CYP3A4 Interaction

Tabimorelin demonstrated moderate oral bioavailability in preclinical species, with an absolute bioavailability of approximately 30% in beagle dogs and a half-life of 4.1 ± 0.4 hours. This was lower than capromorphone (44% in dogs) and MK-677 (reported >60%), suggesting that tabimorelin's oral exposure may require higher doses or careful formulation optimisation compared to alternative GHS-R1a agonists.

A significant drug-drug interaction liability emerged during clinical development: tabimorelin is a mechanism-based inhibitor of CYP3A4. In a clinical interaction study with midazolam (a CYP3A4 substrate), a single dose of tabimorelin increased midazolam AUC by 64%, and this effect increased to 93% after 7 days of repeated dosing. Even after a 7-day washout period, midazolam AUC remained 45% above baseline, indicating prolonged enzyme inhibition.

This CYP3A4 inhibition was identified as a contributing factor to tabimorelin's discontinuation, alongside lack of efficacy in Phase 2 trials.

Clinical Development Outcome

Tabimorelin advanced to Phase 2 clinical trials for growth hormone deficiency in adults. A multicenter, randomized, double-blind, placebo-controlled study enrolled 97 GH-deficient adults treated with NN703 or placebo . The results were disappointing: after 1 week of treatment, GH peak and AUC values following the final dose were similar between NN703 and placebo groups. While serum GH responses were greater after the first NN703 dose compared to placebo, this difference lost statistical significance after correction for lower BMI in the treatment group .

These efficacy findings, combined with the CYP3A4 inhibition liability, led to the discontinuation of tabimorelin's development . The compound remains available as a research tool for studying GHS-R1a pharmacology, but its therapeutic potential was ultimately limited by insufficient efficacy and unfavorable drug-drug interaction profile.

Conclusion

Tabimorelin represents an instructive case in ghrelin receptor drug discovery. Its oral bioavailability and potent GH-releasing activity validated the concept of small-molecule GHS-R1a agonists, but its broader endocrine effects, orexigenic metabolic actions, and significant CYP3A4 inhibition proved problematic for chronic therapeutic use. The compound's research legacy lies in illuminating the interconnected roles of ghrelin and leptin signaling in energy balance and demonstrating the challenges of achieving selective GH stimulation without confounding metabolic and endocrine effects. For researchers studying GHS-R1a biology, tabimorelin remains a valuable pharmacological tool, particularly for investigations where its broader hormonal footprint is the object of study rather than a liability to be avoided.